Focus Advisor Solutions LLC raised its stake in Insulet Corporation (NASDAQ:PODD – Free Report) by 418.8% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 21,806 shares of the medical instruments supplier’s stock after buying an additional 17,603 shares during the quarter. Focus Advisor Solutions LLC’s holdings in Insulet were worth $2,845,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of the company. Bogart Wealth LLC increased its stake in shares of Insulet by 163.5% in the third quarter. Bogart Wealth LLC now owns 419 shares of the medical instruments supplier’s stock valued at $55,000 after purchasing an additional 260 shares during the period. Public Sector Pension Investment Board grew its holdings in Insulet by 74.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 19,671 shares of the medical instruments supplier’s stock worth $2,750,000 after buying an additional 8,411 shares in the last quarter. Global Retirement Partners LLC grew its holdings in Insulet by 478.7% in the 3rd quarter. Global Retirement Partners LLC now owns 3,281 shares of the medical instruments supplier’s stock worth $428,000 after buying an additional 2,714 shares in the last quarter. Edgestream Partners L.P. acquired a new stake in Insulet in the 3rd quarter valued at approximately $9,429,000. Finally, Teachers Retirement System of The State of Kentucky raised its stake in Insulet by 444.8% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 173,737 shares of the medical instruments supplier’s stock valued at $22,668,000 after acquiring an additional 141,849 shares in the last quarter.
Analysts Set New Price Targets
PODD has been the subject of several recent analyst reports. Wells Fargo & Company increased their price target on Insulet from $144.00 to $172.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 5th. Canaccord Genuity Group reduced their price objective on shares of Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a report on Thursday, August 6th. BTIG Research lowered shares of Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Stifel Nicolaus lowered shares of Insulet from a “buy” rating to a “hold” rating and decreased their target price for the company from $180.00 to $165.00 in a research report on Wednesday. Finally, Barclays raised their target price on shares of Insulet from $150.00 to $165.00 and gave the company an “equal weight” rating in a research note on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $184.33.
Insulet Trading Down 3.0%
Shares of PODD stock opened at $133.17 on Friday. The stock has a 50-day simple moving average of $142.28 and a 200 day simple moving average of $170.66. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $342.13. The stock has a market capitalization of $9.24 billion, a P/E ratio of 21.69, a P/E/G ratio of 1.01 and a beta of 1.06. The company has a quick ratio of 1.83, a current ratio of 2.51 and a debt-to-equity ratio of 0.60.
Insulet (NASDAQ:PODD – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, topping the consensus estimate of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The firm had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. During the same period in the previous year, the business earned $1.24 earnings per share. Insulet’s revenue for the quarter was up 19.2% compared to the same quarter last year. On average, sell-side analysts expect that Insulet Corporation will post 6.76 earnings per share for the current fiscal year.
Insulet Company Profile
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
Read More
- Five stocks we like better than Insulet
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
